Corgenix to Develop Diagnostic Tests for Bioterrorism Agents under Multi-Million Dollar NIH Contract Awarded to Tulane University.

DENVER -- New Diagnostics to Utilize Corgenix' Proprietary Technology Platform; Expands Company Presence into BioDefense

Corgenix Medical Corporation (OTC BB: CONX), in partnership with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and two corporate partners, will develop and manufacture improved diagnostic tests for viral hemorrhagic fevers under a $3.8 million grant awarded by the National Institutes of Health (NIH).

Under the NIH grant, Tulane University will lead a three-year study designed to develop better tests for viral hemorrhagic fevers, which are caused by arenaviruses known to be potential bioterrorism agents due to their high fatality rate and ease of transmission from person-to-person. Corgenix will work with Tulane and others to develop and manufacture a commercialized product that will enable rapid detection of the disease.

"We are very excited to work with these partners to develop diagnostic test kits that have significant implications for not only public health, but also biodefense," commented Douglass Simpson, President and CEO of Corgenix. "These new products, which will utilize our proprietary ELISA technology, will compliment our existing diagnostic product portfolio and extend our company's reach into the bioterrorism diagnostic test field."

Viral hemorrhagic fevers, including Lassa fever, are particularly common in West Africa, where 10-16 percent of people admitted to hospitals are affected. As with any bioterrorism agent, an important factor in dealing with viral hemorrhagic fevers is the ability to diagnose them rapidly. The goal of this study is to develop effective tests that would not require biosafety level 4 (the highest level) laboratories, the requirement for tests currently available, thus ensuring increased availability of tests and timely diagnosis.

The study will be led by Robert Garry, Professor of Microbiology and Immunology at the Tulane University School of Medicine. Corgenix will partner in this project with Dr. Garry's team, as well as the U.S. Army Medical Research Institute of Infectious Diseases in Ft. Detrick, MD, Autoimmune Technologies, LLC of New Orleans, and BioFactura, Inc. of Rockville, MD.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

About Autoimmune Technologies, LLC

Autoimmune Technologies is a privately held early-stage biomedical company. In addition to developing its own technologies, Autoimmune has licensed several proprietary breakthrough technologies from Tulane University School of Medicine and is working to make them commercially available to the medical community.

About BioFactura, Inc.

BioFactura offers a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. BioFactura is also developing technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.